Kyto Biopharma Inc. (KBPH) Financials Nov 10, 2014
Post# of 250675
Posted On: 11/17/2014 2:25:18 AM
Kyto Biopharma Inc. (KBPH) Financials Nov 10, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Kyto Biopharma Inc.
Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 0 0 0 0 0
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 0 0 0 0 0
Depreciation - - 0 0 0
Amortization of Intangibles - - 0 0 0
Gross Income 0 0 0 0 0
2010 2011 2012 2013 2014 5-year trend
SG&A Expense - - 122,020 58,726 80,801
Research & Development - - 0 0 -
Other SG&A - - 122,020 58,726 80,801
Other Operating Expense - - 0 0 0
Unusual Expense 265,931 43,690 0 0 0
EBIT after Unusual Expense (265,931) (43,690) 0 0 0
Non Operating Income/Expense - - (6) (173,624) 0
Non-Operating Interest Income - - 0 0 0
Equity in Affiliates (Pretax) - - 0 - -
Interest Expense 31,903 122,514 68,577 18,137 7,800
Gross Interest Expense 31,903 122,514 68,577 18,137 7,800
Interest Capitalized - - 0 0 0
Pretax Income (591,293) (518,258) (190,603) (250,487) (88,601)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic - - 0 - -
Income Tax - Current Foreign - - 0 - -
Income Tax - Deferred Domestic - - 0 - -
Income Tax - Deferred Foreign - - 0 - -
Income Tax Credits - - 0 - -
Equity in Affiliates - - 0 0 -
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income (591,293) (518,258) (190,603) (250,487) (88,601)
Minority Interest Expense 0 0 0 0 0
Net Income (591,293) (518,258) (190,603) (250,487) (88,601)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - - 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (591,293) (518,258) (190,603) (250,487) (88,601)
Preferred Dividends 0 0 28,008 24,053 25,354
Net Income Available to Common (591,293) (518,258) (218,611) (274,540) (113,955)
EPS (Basic) (0.05) (0.04) (0.01) (0.02) (0.01)
Basic Shares Outstanding 12.74M 13M 13M 13M 13M
EPS (Diluted) (0.05) (0.04) (0.01) (0.02) (0.01)
Diluted Shares Outstanding 12.74M 13M 13M 13M 13M
EBITDA (293,369) (352,050) (122,020) (58,726) (80,801)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Kyto Biopharma Inc.
Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 0 0 0 0 0
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 0 0 0 0 0
Depreciation - - 0 0 0
Amortization of Intangibles - - 0 0 0
Gross Income 0 0 0 0 0
2010 2011 2012 2013 2014 5-year trend
SG&A Expense - - 122,020 58,726 80,801
Research & Development - - 0 0 -
Other SG&A - - 122,020 58,726 80,801
Other Operating Expense - - 0 0 0
Unusual Expense 265,931 43,690 0 0 0
EBIT after Unusual Expense (265,931) (43,690) 0 0 0
Non Operating Income/Expense - - (6) (173,624) 0
Non-Operating Interest Income - - 0 0 0
Equity in Affiliates (Pretax) - - 0 - -
Interest Expense 31,903 122,514 68,577 18,137 7,800
Gross Interest Expense 31,903 122,514 68,577 18,137 7,800
Interest Capitalized - - 0 0 0
Pretax Income (591,293) (518,258) (190,603) (250,487) (88,601)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic - - 0 - -
Income Tax - Current Foreign - - 0 - -
Income Tax - Deferred Domestic - - 0 - -
Income Tax - Deferred Foreign - - 0 - -
Income Tax Credits - - 0 - -
Equity in Affiliates - - 0 0 -
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income (591,293) (518,258) (190,603) (250,487) (88,601)
Minority Interest Expense 0 0 0 0 0
Net Income (591,293) (518,258) (190,603) (250,487) (88,601)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - - 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (591,293) (518,258) (190,603) (250,487) (88,601)
Preferred Dividends 0 0 28,008 24,053 25,354
Net Income Available to Common (591,293) (518,258) (218,611) (274,540) (113,955)
EPS (Basic) (0.05) (0.04) (0.01) (0.02) (0.01)
Basic Shares Outstanding 12.74M 13M 13M 13M 13M
EPS (Diluted) (0.05) (0.04) (0.01) (0.02) (0.01)
Diluted Shares Outstanding 12.74M 13M 13M 13M 13M
EBITDA (293,369) (352,050) (122,020) (58,726) (80,801)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)